Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles
Cynthia Challener, PhD for Pharmaceutical Technology
March 2025, Volume 49, Issue 2
Recently, our Commercial Operating Officer, Grant Boldt, PhD lent his thoughts to an industry article from Pharmaceutical Technology addressing the challenges posed by the limited bioavailability and stability in traditional drug development and delivery. He and other industry experts highlighted efforts to enhance stability and solubility, facilitate cellular entry, and ideally allow effective targeting of specific cells, tissues, and/or organs via alternative nanoscale technologies.
At CPTx, we use proprietary technologies including programmable single-stranded DNA fabrication processes and AI-supported molecular design to overcome existing development challenges and advance new genetic medicines to market.
Learn more about the problems and solutions in this Pharmaceutical Technology article by clicking here. Or reach out any time at info@cptx.bio to have a discussion.